The role of CD147 expression in prostate cancer: a systematic review and meta-analysis

Figures & data

Figure 1 Flowchart showing study-selection procedure.

Table 1 Characteristics of the eligible studies included in the meta-analysis

Study	Study location	Sample size, n		Age, yearsa		CD147 positive, %		Measurement	NOS score
		Case	Control	Case	Control	Case	Control
Cai et al^Citation23	Asia	56	22	53–80	59–89	64.3	9.1	IHC	6
Feng and Feng^Citation22	Asia	60	15	59–89	59–80	61.7	26.7	IHC	7
Han et al^Citation18	Asia	62	30	58–86	NR	82.3	13.3	IHC	7
He et al^Citation19	Asia	101	90	73.5	NR	66.3	23.3	IHC	7
Wang et al^Citation21	Asia	54	40	33–77	35–79	84.4	17.5	IHC	6
Bi et al^Citation20	Asia	300	20	45–86	46–72	62.0	5.0	IHC	7
Madigan et al^Citation24	Australia	120	15	46–72	53–72	65.0	13.3	IHC	8
Pértega-Gomes et al^Citation25	Europe	167	134	46–74	NR	49.7	40.8	IHC	8

Note:

a Age data presented as mean or range.

Abbreviations: IHC, immunohistochemistry; NOS, Newcastle-Ottawa Scale; NR, not reported.

Figure 2 Forest plots for the relationship between CD147 expression and prostate cancer.

Note: The data are for case versus control.
Abbreviations: CI, confidence interval; OR, odds ratio.

Figure 3 Subgroup analysis of the relationship between CD147 expression and prostate cancer.

Note: The data are for case versus control.
Abbreviations: CI, confidence interval; OR, odds ratio.

Figure 4 Forest plots for the relationship between CD147 expression and clinicopathological characteristics of prostate cancer.

Abbreviations: CI, confidence interval; OR, odds ratio; PSA, prostate-specific antigen; TNM, tumor–node–metastasis.

Figure 5 Sensitivity analyses of the summary odds ratio coefficients.

Abbreviations: CI, confidence interval; OR, odds ratio; TNM, tumor–node–metastasis.

Figure 6 Funnel plots of publication biases.

Abbreviations: CI, confidence interval; OR, odds ratio; SE, standard error; TNM, tumor–node–metastasis.

CaiCYWuCYYangYFLiSRShiXMExpression and clinical significance of CD147 protein in human prostate cancerJ Clin Res20153220882090

 Google Scholar

FengMEFengLTo investigate the expression of the STAT3 and CD147 in human prostate cancerJ Nanchang Univ2010501215

 Google Scholar

HanZDBiXCQinWJCD147 expression indicates unfavourable prognosis in prostate cancerPathol Oncol Res200915336937419048397

 PubMed Web of Science ®Google Scholar

HeHCHanZDDaiQSExpression and significance of CDl47 protein inprostate cancerZhonghua Yi Xue Za Zhi2009891844184619953931

 PubMedGoogle Scholar

WangQZhangJGWangWExpression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stagesGenet Mol Res2015146844685126125892

 PubMedGoogle Scholar

BiXCLiuJMZhengXGOver-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomyClin Invest Med2011346E35822129926

 PubMed Web of Science ®Google Scholar

MadiganMCKingsleyEACozziPJDelpradoWJRussellPJLiYThe role of extracellular matrix metalloproteinase inducer protein in prostate cancer progressionCancer Immunol Immunother20085791367137918273614

 PubMed Web of Science ®Google Scholar

Pértega-GomesNVizcaínoJRMiranda-GonçalvesVMonocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancerBMC Cancer20111131221787388

 PubMed Web of Science ®Google Scholar